Europe in-vitro toxicology testing market is expected to reach USD 10735 Million by 2023 from USD 5841 Million in 2018, growing at a CAGR of 12.95% for the next five years 2018-2023. In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is very essential in drug discovery as identifies the toxic effects of new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.
Increasing chronic diseases, growing aging population, rising technological advancements, growing demand for healthy life style, availability of government supported anti-animal testing laws, and existence of favorable regulatory policies (such as European government banned the production & sale of all animal tested cosmetics in Europe) are driving the growth of in-vitro toxicology testing market in Europe. However, high cost of technologies and lack of awareness on the in-vitro toxicology testing utilization are restraining the growth of in-vitro toxicology testing market in Europe.
Europe in-vitro toxicology testing market is segmented based on the product, type, toxicity endpoints & tests, technology, method, and industry. Based on product, the market is further sub-segmented as assays, reagent & labware, and service. Assays segment is estimated to command the largest share of Europe in-vitro toxicology testing market by product in 2016. Based on type, the market is segmented as ADME, dose, and toxic substance.
Toxicity endpoints & tests is further segmented as systemic toxicity, dermal toxicity, carcinogenicity, ocular toxicity, skin sensitization & irritation, genotoxicity, neurotoxicity, and organ toxicity. Systemic toxicity is estimated to command the largest share of Europe in-vitro toxicology testing market by toxicity endpoints & tests in 2016. Technology is further segmented as OMICS technologies & cell culture technology.
By method, the market is segmented as in-silico method, biochemical assays, cellular assays, and ex vivo models. In-silico method is estimated to command the largest share of Europe in-vitro toxicology testing market by method in 2016. The market, by industry, is sub-segmented as cosmetics & household products, pharmaceutical, diagnostics, chemical, & food. The cosmetics & household products industry is estimated to account for the largest market share of Europe in-vitro toxicology testing market by industry in 2016.
On the basis of geographical areas, Europe in-vitro toxicology testing market is segmented as U.K., Germany, France, Italy, and Spain. Germany is estimated to account for the largest share of the Europe in-vitro toxicology testing market in 2016, whereas France is estimated to grow at the highest CAGR during the forecast period 2016-2021.
The key players in in-vitro toxicology testing market include, Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.), and Cyprotex (U.K.), among others.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Assays
5.1.3 Reagents & Labware
5.1.4 Services Growth Hormone Therapy
5.2 Type
5.2.1 Introduction
5.2.2 ADME (Absorption, Distribution, Metabolism, and Excretion)
5.2.3 Dose
5.2.4 Toxic Substance
5.3 Toxicity Endpoints & Tests
5.3.1 Introduction
5.3.2 Systemic Toxicity
5.3.3 Dermal Toxicity
5.3.4 Carcinogenicity
5.3.5 Ocular Toxicity
5.3.6 Skin Sensitization & Irritation
5.3.7 Genotoxicity
5.3.8 Neurotoxicity
5.3.9 Organ Toxicity
5.3.10 Other Toxicity Endpoints & Tests
5.4 Technology
5.4.1 Introduction
5.4.2 OMICS Technologies
5.4.3 Cell Culture Technology
5.4.4 High-Throughput Technologies
5.4.5 Molecular Imaging Technologies
5.5 Method
5.5.1 Introduction
5.5.2 In-Silico Methods
5.5.3 Biochemical Assays
5.5.4 Cellular Assays
5.5.5 Ex-Vivo Models
5.6 Industry
5.6.1 Introduction
5.6.2 Cosmetics and Household Products
5.6.3 Diagnostics
5.6.4 Pharmaceuticals
5.6.5 Food Industry
5.6.6 Chemicals
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Covance, Inc. (A subsidiary of LabCorp) (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Agilent Technologies, Inc. (U.S.)
8.3 Bio-Rad Laboratories, Inc. (U.S.)
8.4 Eurofins Scientific SE (Luxembourg)
8.5 General Electric Company (U.S.)
8.6 BioReliance, Inc. (U.S.)
8.7 Charles River Laboratories International, Inc. (U.S.)
8.8 Thermo Fisher Scientific, Inc. (U.S.)
8.9 Catalent (U.S.)
8.10 Cyprotex (U.K.)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
